Endothelium

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Study Illustrates Zeropollution's Enhancing Skin's Resilience to Environmental Damage

Retrieved on: 
Tuesday, March 5, 2024

MADRID, March 5, 2024 /PRNewswire/ -- A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level.

Key Points: 
  • This patented multi-herbal cosmeceutical has been crafted to synergistically strengthen the skin's protective barrier against environmental insults through an "inside out" approach.
  • The study led by Laurent Peno-Mazzarino was published in the Journal of Current Issues in Molecular Biology in January 2024.
  • This encompasses reactive molecules generated by factors such as UV radiation, pollution, and other environmental stressors that can damage cells and tissues.
  • In this study, Zeropollution successfully counteracted the adverse effects of urban dust on the heart rate of zebra fish embryos.

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Retrieved on: 
Tuesday, February 13, 2024

LA JOLLA, Calif., Feb. 13, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, Auxora™, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.

Key Points: 
  • CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.
  • "Through KOURAGE, we aim to determine how Auxora can benefit patients with severe AKI and potentially reduce the high mortality rate associated with this disease."
  • AKI is classified as stages 1, 2 and 3 depending on the degree of kidney injury.
  • A single dose of Auxora after IRI increased GFR by 61% and decreased mononuclear (inflammatory) cell infiltration by 30%.

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

Retrieved on: 
Tuesday, February 6, 2024

Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.

Key Points: 
  • Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.
  • This can lead to fluid accumulation and retinal thickening – a key feature of DME.
  • They demonstrated that these senescent cells contribute to loss of barrier function, which can cause leaky blood vessels.
  • This research further supports the potential for senolytic medicines to address the significant unmet need with current standard of care.”

Element to Present Data on New Products and Multi-Omics Capabilities at AGBT

Retrieved on: 
Monday, February 5, 2024

Never before have so many data points been available to researchers at this cost and speed.

Key Points: 
  • Never before have so many data points been available to researchers at this cost and speed.
  • Cloudbreak UltraQ is the industry's first commercial Q50 kit capable of generating 100-fold higher accuracy than currently available published specifications.
  • Trinity is Element's on-board enrichment solution that simplifies targeted sequencing, to provide users with a new level of convenience, flexibility, and performance.
  • AVITI24 streamlines these studies and data collection to enable rapid recursive learning with broad applications across systems biology.

Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery

Retrieved on: 
Thursday, January 4, 2024

Apertura Gene Therapy , a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).

Key Points: 
  • Apertura Gene Therapy , a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).
  • This transportation mechanism mediates crossing of the blood-brain barrier (BBB) to enable gene therapy delivery throughout the central nervous system (CNS).
  • “Our TfR1 capsids, with their well-characterized mechanism of action, offer the unique advantage of significantly reducing human translation risk – a major historical challenge of engineering novel AAV capsids.
  • Apertura is currently advancing two programs utilizing its TfR1 capsids for undisclosed neurologic conditions and is leveraging its platform technologies to engineer novel payloads to regulate genetic expression and develop additional AAV capsids targeting specific human receptors.

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Vascular Perfusion Solutions and Unravel Biosciences announce partnership to modulate endothelial activation during heart preservation to improve heart transplant outcomes

Retrieved on: 
Monday, November 27, 2023

BOSTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vascular Perfusion Solutions (VPS) and Unravel Biosciences, Inc. (“Unravel”) are partnering to develop a proprietary perfusion solution that will enhance organ viability during transport and reduce the risk of acute rejection following transplantation.

Key Points: 
  • BOSTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vascular Perfusion Solutions (VPS) and Unravel Biosciences, Inc. (“Unravel”) are partnering to develop a proprietary perfusion solution that will enhance organ viability during transport and reduce the risk of acute rejection following transplantation.
  • The partnership utilizes Unravel’s target and drug discovery platform, BioNAV™, which leverages a gene expression network AI model of human health to advance drugs for complex diseases in a target-agnostic manner, to identify small molecule modulators of endothelial activation.
  • Acute organ rejection is the leading cause of transplant failure, resulting in a growing interest in improving organ preservation and ex-vivo heart perfusion techniques increasing transport time while reducing the harsh impacts of ischemic injury.
  • VPS stands as a trailblazer in the field of organ preservation and transplant research, committed to pushing the boundaries of science to enhance transplant patient outcomes.

Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

Retrieved on: 
Friday, December 22, 2023

Ph.D., “Cellusion”), a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to our regenerative medicine product “iPS cell-derived corneal endothelial cell substitute” (“CLS001”) for the treatment of bullous keratopathy.

Key Points: 
  • Ph.D., “Cellusion”), a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to our regenerative medicine product “iPS cell-derived corneal endothelial cell substitute” (“CLS001”) for the treatment of bullous keratopathy.
  • FDA grants ODD if the drug meets specific criteria, the treatment, diagnosis, or prevention of rare diseases that affect less than 200,000 people in the United States.
  • The ODD qualifies sponsors for incentives, including tax credits for qualified clinical (in humans) testing, waiver of the prescription drug user fee and potential 7 years of market exclusivity after FDA approval.
  • With this designation, we will further accelerate the global development of CLS001 and aim to contribute to patients around the world who are waiting for the treatment.